Participants
sarcoidosis, pSS, ’s Syndrome, amyloidosis, glaucoma, head and neck radiation, Systemic lupus erythematosus
SARCOIDOSIS, POSITIVE, ACQUIRED IMMUNODEFICIENCY SYNDROME, GRAFT VERSUS HOST DISEASE, DISEASE, LYMPHOCYTIC INFILTRATION, HEPATITIS C INFECTION, SYNDROMES, AMYLOIDOSIS, GLAUCOMA, IGG4-RELATED DISEASE, RHEUMATOID ARTHRITIS, SYSTEMIC LUPUS ERYTHEMATOSUS
Patients were consecutively recruited referred to Department of Rheumatology, Stomatology and Ophthalmology, Affiliated Huai'an Hospital of Xuzhou Medical University. Eligible patients were diagnosed as having pSS according to the American College of Rheumatology (ACR) Diagnostic Criteria for Sjögren’s Syndrome. At least two syndromes with following three objective features will meet the criteria: (1)patients are newly diagnosed with pSS and have not received previous treatments; (2) Positive serum anti-SSA (Ro) and/or anti-SSB (La); (3) Labial salivary gland biopsy exhibiting focal lymphocytic infiltration with a focus score ≥ 1 focus/4 mmThe exclusion criteria for all patients were: (1) not currently using daily eye drops for glaucoma, and has not had corneal surgery or cosmetic eyelid surgery in the last 5 years; (2) any of the following conditions: history of head and neck radiation treatment, hepatitis C infection, acquired immunodeficiency syndrome, sarcoidosis, amyloidosis, graft versus host disease, IgG4-related disease; (3) other systemic conditions that could affect the progression of pSS, such as Systemic lupus erythematosus and Rheumatoid arthritis; (4) a history disease of chronic obstructive sialadenitis disease; (5) status of pregnancy or lactation.Patients were interviewed to provide of informations including their socio-demographic characteristics, life-style factors, compliance to drugs and self-care knowledge at study entry. Clinical assessments of disease activity were also performed at the first screening.